Novo Nordisk $NVO ( ▼ 0.65% ) tumbled after disappointing trial results suggested its experimental obesity treatment may not reclaim leadership in the booming weight-loss market. The company’s new drug candidate, CagriSema, failed to outperform Eli Lilly’s blockbuster therapy, dealing a major blow to expectations that Novo would leapfrog its rival.
In a head-to-head study, patients on CagriSema lost 23% of their body weight after 84 weeks, compared with 25.5% for tirzepatide, Eli Lilly’s dominant GLP-1 therapy. Novo said it plans additional trials, including testing higher-dose combinations, in hopes of improving efficacy.
From pioneer to playing catch-up
Novo was first to commercialize modern GLP-1 weight-loss drugs, but momentum has shifted decisively toward Eli Lilly $LLY, whose treatments have captured market share and investor enthusiasm. The weaker trial results reinforce concerns that Novo’s pipeline may struggle to produce a clear next-generation winner.
Competition is also intensifying as multiple pharmaceutical companies race to enter the multibillion-dollar obesity drug market. Novo recently warned that its own sales could decline between 5% and 13% in 2026, underscoring how quickly leadership can change in this space.
The pill race heats up
Novo is not without countermeasures. The company recently launched an oral version of Wegovy, the first GLP-1 weight-loss pill available, and early demand has reportedly been strong. However, Eli Lilly is preparing to launch its own oral treatment, orforglipron, later this year, setting up another high-stakes showdown.
For investors, the message is clear: the obesity drug boom remains enormous, but dominance is far from settled. Clinical results, manufacturing capacity, pricing, and convenience will all shape who ultimately controls one of the most lucrative pharmaceutical markets in history.